-
公开(公告)号:US20160251442A1
公开(公告)日:2016-09-01
申请号:US15051580
申请日:2016-02-23
Applicant: REGENERON PHARMACEUTICALS, INC.
Inventor: Nicholas J. PAPADOPOULOS , Gavin THURSTON , Jessica R. KIRSHNER , Marcus P. KELLY , Thomas NITTOLI , Frank J. DELFINO
CPC classification number: C07K16/2866 , A61K31/537 , A61K47/6803 , A61K47/6849 , A61K2039/505 , C07K16/2869 , C07K2317/21 , C07K2317/24 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/77 , C07K2317/92 , C07K2317/94
Abstract: The present invention provides antibodies that bind to prolactin receptor (PRLR) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human PRLR with high affinity. In certain embodiments, the invention includes antibodies that bind PRLR and block prolactin-mediated cell signaling. In other embodiments, the invention includes antibodies that bind PRLR but do not block prolactin-mediated cell signaling. The antibodies of the invention may be fully human antibodies. The invention includes anti-PRLR antibodies conjugated to a cytotoxic agent, radionuclide, or other moiety detrimental to cell growth or proliferation. The antibodies of the invention are useful for the treatment of various cancers as well as other PRLR-related disorders. The present invention also includes antibody drug conjugates comprising an antibody or antigen-binding fragment thereof that specifically binds a class I cytokine receptor, wherein the antibody or antigen-binding fragment thereof is conjugated to a cytotoxic agent.
-
公开(公告)号:US20210147557A1
公开(公告)日:2021-05-20
申请号:US16918656
申请日:2020-07-01
Applicant: REGENERON PHARMACEUTICALS, INC.
Inventor: Jessica R. KIRSHNER , Douglas MACDONALD , Gavin THURSTON , Joel H. MARTIN , Frank DELFINO , Thomas NITTOLI , Marcus KELLY
IPC: C07K16/28 , A61K39/395 , A61K45/06 , A61K47/68 , C07K16/30
Abstract: The present invention provides antibodies that bind to the class Ill variant of EGFR (EGFRvIII) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human EGFRvIII with high affinity. The antibodies of the invention may be fully human antibodies. The invention includes anti-EGFRvIII antibodies conjugated to a cytotoxic agent, radionuclide, or other moiety detrimental to cell growth or proliferation. The antibodies of the invention are useful for the treatment of various cancers.
-
公开(公告)号:US20180312594A1
公开(公告)日:2018-11-01
申请号:US16033477
申请日:2018-07-12
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor: Jessica R. KIRSHNER , Douglas MACDONALD , Gavin THURSTON , Joel H. MARTIN , Frank DELFINO , Thomas NITTOLI , Marcus KELLY
Abstract: The present invention provides antibodies that bind to the class III variant of EGFR (EGFRvIII) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human EGFRvIII with high affinity. The antibodies of the invention may be fully human antibodies. The invention includes anti-EGFRvIII antibodies conjugated to a cytotoxic agent, radionuclide, or other moiety detrimental to cell growth or proliferation. The antibodies of the invention are useful for the treatment of various cancers.
-
公开(公告)号:US20160304615A1
公开(公告)日:2016-10-20
申请号:US15170628
申请日:2016-06-01
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor: Jessica R. KIRSHNER , Douglas MACDONALD , Gavin THURSTON , Joel H. MARTIN , Frank DELFINO , Thomas NITTOLI , Marcus KELLY
IPC: C07K16/28 , A61K39/395 , A61K45/06 , C07K16/30 , A61K47/48
CPC classification number: C07K16/2863 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K47/6803 , A61K47/6851 , A61K2039/505 , A61K2039/507 , C07K16/30 , C07K16/3015 , C07K16/3023 , C07K16/3069 , C07K2317/33 , C07K2317/34 , C07K2317/565 , C07K2317/77 , C07K2317/92
Abstract: The present invention provides antibodies that bind to the class III variant of EGFR (EGFRvIII) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human EGFRvIII with high affinity. The antibodies of the invention may be fully human antibodies. The invention includes anti-EGFRvIII antibodies conjugated to a cytotoxic agent, radionuclide, or other moiety detrimental to cell growth or proliferation. The antibodies of the invention are useful for the treatment of various cancers.
-
公开(公告)号:US20150259423A1
公开(公告)日:2015-09-17
申请号:US14643886
申请日:2015-03-10
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor: Jessica R. KIRSHNER , Douglas MACDONALD , Gavin THURSTON , Joel H. MARTIN , Frank DELFINO , Thomas NITTOLI , Marcus KELLY
IPC: C07K16/28 , A61K39/395 , A61K45/06 , A61K47/48
CPC classification number: C07K16/2863 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K47/6803 , A61K47/6851 , A61K2039/505 , A61K2039/507 , C07K16/30 , C07K16/3015 , C07K16/3023 , C07K16/3069 , C07K2317/33 , C07K2317/34 , C07K2317/565 , C07K2317/77 , C07K2317/92
Abstract: The present invention provides antibodies that bind to the class III variant of EGFR (EGFRvIII) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human EGFRvIII with high affinity. The antibodies of the invention may be fully human antibodies. The invention includes anti-EGFRvIII antibodies conjugated to a cytotoxic agent, radionuclide, or other moiety detrimental to cell growth or proliferation. The antibodies of the invention are useful for the treatment of various cancers.
Abstract translation: 本发明提供了结合EGFR(EGFRvIII)的III类变体的抗体及其使用方法。 根据某些实施方案,本发明的抗体以高亲和力结合人EGFRvIII。 本发明的抗体可以是完全人抗体。 本发明包括与细胞毒性剂,放射性核素或对细胞生长或增殖有害的其它部分缀合的抗EGFRvIII抗体。 本发明的抗体可用于治疗各种癌症。
-
公开(公告)号:US20150056222A1
公开(公告)日:2015-02-26
申请号:US14530265
申请日:2014-10-31
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor: Nicholas J. PAPADOPOULOS , Gavin THURSTON , Jessica R. KIRSHNER , Marcus P. KELLY , Thomas NITTOLI , Frank J. DELFINO , William C. OLSON , Yashu LIU
CPC classification number: A61K47/48561 , A61K39/3955 , A61K47/48384 , A61K47/6803 , A61K47/6849 , C07K16/2869 , C07K16/30 , C07K2317/21 , C07K2317/73 , C07K2317/76 , C07K2317/77 , C07K2317/92
Abstract: The present invention provides antibodies that bind to prolactin receptor (PRLR) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human PRLR with high affinity. In certain embodiments, the invention includes antibodies that bind PRLR and block prolactin-mediated cell signaling. In other embodiments, the invention includes antibodies that bind PRLR but do not block prolactin-mediated cell signaling. According to certain embodiments, the invention includes antibodies that bind to the first fibronectin-like type III domain of the extracellular domain of PRLR. The antibodies of the invention may be fully human antibodies. The invention includes anti-PRLR antibodies conjugated to a cytotoxic agent, radionuclide, or other moiety detrimental to cell growth or proliferation. The antibodies of the invention are useful for the treatment of various cancers as well as other PRLR-related disorders. The present invention also includes antibody drug conjugates comprising an antibody or antigen-binding fragment thereof that specifically binds a class I cytokine receptor, wherein the antibody or antigen-binding fragment thereof is conjugated to a cytotoxic agent.
Abstract translation: 本发明提供了结合催乳素受体(PRLR)的抗体及其使用方法。 根据某些实施方案,本发明的抗体以高亲和力结合人PRLR。 在某些实施方案中,本发明包括结合PRLR并阻断催乳素介导的细胞信号传导的抗体。 在其它实施方案中,本发明包括结合PRLR但不阻断催乳素介导的细胞信号传导的抗体。 根据某些实施方案,本发明包括结合PRLR细胞外结构域的第一纤连蛋白样III型结构域的抗体。 本发明的抗体可以是完全人抗体。 本发明包括与细胞毒性剂,放射性核素或对细胞生长或增殖有害的其它部分缀合的抗PRLR抗体。 本发明的抗体可用于治疗各种癌症以及其它PRLR相关疾病。 本发明还包括抗体药物缀合物,其包含特异性结合I类细胞因子受体的抗体或其抗原结合片段,其中所述抗体或其抗原结合片段与细胞毒性剂缀合。
-
公开(公告)号:US20150056221A1
公开(公告)日:2015-02-26
申请号:US14464297
申请日:2014-08-20
Applicant: REGENERON PHARMACEUTICALS, INC.
Inventor: Nicholas J. PAPADOPOULOS , Gavin THURSTON , Jessica R. KIRSHNER , Marcus P. KELLY , Thomas NITTOLI , Frank J. DELFINO
IPC: A61K47/48 , A61K31/537 , C07K16/28
CPC classification number: C07K16/2866 , A61K31/537 , A61K47/6803 , A61K47/6849 , A61K2039/505 , C07K16/2869 , C07K2317/21 , C07K2317/24 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/77 , C07K2317/92 , C07K2317/94
Abstract: The present invention provides antibodies that bind to prolactin receptor (PRLR) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human PRLR with high affinity. In certain embodiments, the invention includes antibodies that bind PRLR and block prolactin-mediated cell signaling. In other embodiments, the invention includes antibodies that bind PRLR but do not block prolactin-mediated cell signaling. The antibodies of the invention may be fully human antibodies. The invention includes anti-PRLR antibodies conjugated to a cytotoxic agent, radionuclide, or other moiety detrimental to cell growth or proliferation. The antibodies of the invention are useful for the treatment of various cancers as well as other PRLR-related disorders. The present invention also includes antibody drug conjugates comprising an antibody or antigen-binding fragment thereof that specifically binds a class I cytokine receptor, wherein the antibody or antigen-binding fragment thereof is conjugated to a cytotoxic agent.
Abstract translation: 本发明提供了结合催乳素受体(PRLR)的抗体及其使用方法。 根据某些实施方案,本发明的抗体以高亲和力结合人PRLR。 在某些实施方案中,本发明包括结合PRLR并阻断催乳素介导的细胞信号传导的抗体。 在其它实施方案中,本发明包括结合PRLR但不阻断催乳素介导的细胞信号传导的抗体。 本发明的抗体可以是完全人抗体。 本发明包括与细胞毒性剂,放射性核素或对细胞生长或增殖有害的其它部分缀合的抗PRLR抗体。 本发明的抗体可用于治疗各种癌症以及其它PRLR相关疾病。 本发明还包括抗体药物缀合物,其包含特异性结合I类细胞因子受体的抗体或其抗原结合片段,其中所述抗体或其抗原结合片段与细胞毒性剂缀合。
-
-
-
-
-
-